Section Review: Oncologic, Endocrine & Metabolic: New cytostatic drugs in the treatment of non-small cell lung cancer

References

• SOUQUET PJ, CHAUVIN F, BOISSEL JP, CELLERINO R, CORMIER Y, GANZ PA, KAASA S, PATER JL, QUOIX E, RAPP E, TUMARELLO D, WILLIAMS J, WOODS BL, BERNARD JP: Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet (1993) 342:19–21.
   PubMed Web of Science ®Google Scholar
• SORENSEN JB: The role of chemotherapy in non-small cell lung cancer. Radiol. Oncol. (1994) 28:386–394.
   Google Scholar
• DONNADIEU N, PAESMANS M, SCULIER J-P: Chemother-apy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer (1991) 7:243–252.
   Google Scholar
• SORENSEN JB: Treatment of non-small cell lung cancer: new cytostatic agents. Lung Cancer (1993) 10:173-187. Review covering the literature on new cytostatic drugs in NSCLC from 1985 to 1993.
   Google Scholar
• MONNIER A, PUJOL JL, CERINNA ML, RIVIERE A, DOUIL-LARD JY, GOUVA S, BENOLIEL C, BERILLE J, LE CESNE A, LE CHEVALIER TK: Fotemustine: French multicenter Phase II study in 67 patients with advanced non small cell lung carcinoma (NSCLC). Lung Cancer (1991) 7(Suppl.):119.
   Google Scholar
• PUJOL JL, MONNIER A, BERILLE J, CERRINA ML, DOUIL-LARD JY, RIVIERE A, GRANDGIRARD A, GOUVA S, BIZZARI JP, LE CHEVALIERT: Phase 11 study of the nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. Br. J. Cancer (1994) 69:1136–1140.
   PubMed Web of Science ®Google Scholar
• RUDD R, ALLEN R, BERILL J, SPIRO SG, TRASK C, SOUHAMIRL: Phase U study of fotemustine in untreated inoper-able non-small-cell lung cancer. Cancer Chemother. Phar-macol. (1994) 34:444–446.
   PubMed Web of Science ®Google Scholar
• RIVIERE A, LE CESNE A, BERILLE J, BAIO S, LE CHEVALIERT: Cisplatin-fotemustine combination in inoperable non-small cell lung cancer preliminary report of a French multicentre Phase 11 trial. Eur. J. Cancer (1994) 30A:587–590.
   PubMed Web of Science ®Google Scholar
• MAROUN JA, MAKSYMIUK A, EISENHAUER E, STEWARDDJ, YOUNG V, PATER J: Phase II study of acivkin in non-small cell lung cancer: a National Cancer Institute of Canada study. Cancer Treat. Rep. (1986) 70:1327–1328.
   PubMedGoogle Scholar
• BONOMI P, FINKELSTEIN D, CHANG A: Phase 11 trial ofacivicin versus etoposide-cisplatin in non-small cell lung cancer. An Eastern Cooperative Oncology Group study. Am. J. Clin. Oncol. (1994) 17:215–217.
   PubMed Web of Science ®Google Scholar
• CHANG AY, KIM K, GLICK J, ANDERSON T, ICARP D,JOHNSON D: Phase U study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J. Natl. Cancer Inst. (1993) 85:388–394.
   PubMed Web of Science ®Google Scholar
• VERWEIJ J, WANDERS J, NIELSEN AL, PAVLIDIS N, CALABRESI F, TEN BOKKEL HIUNINK W, BRUNTSEH U, PICCART M, FRANKLIN H, KAY SB: Phase II studies of elsa:mitrucin in breast can, colorectal cancer, non-small cell lung cancer and ovarian can. EORTC Early Clinical Trials Group. Ann. Oncol. (1994) 5:375–376.
   PubMed Web of Science ®Google Scholar
• SORENSEN JB: Gemcitabine in non-small cell lung can-cer. Lung Cancer (1995) 12\(Suppl. 1):5173–175.
   Google Scholar
• ANDERSON H, LUND B, BACH F, THATCHER N, WALLING J, HANSEN HFI: Single-agent activity of weekly gemci-tabine in advanced non-small-cell lung cancer: a Phase II study. J. Clin. Oncol. (1994) 12:1821–1826.
   PubMed Web of Science ®Google Scholar
• ABRATT RP, BEZWODA WR, FALKSON G, GOEDHALS L, HACKING D, RUGG TA: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a Phase 11 study. J. Clin. Oncol. (1994) 12:1535–1540.
   PubMed Web of Science ®Google Scholar
• GESME DH, JETT JR, SCHREFFLER DD, SU JQ, MAILL1ARD JA, FOLEY JF, 'CROOK JE, MAKSYMIUK AW, HATFIELD AK, EBBERT LP, PFEIFLE DM, MORTON RF, TSCHE11ER LK, SCHAEFER PL: A randomized Phase 11 trial of amonafide or trirnetrexate in patients with advanced A, non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. Cancer (1993) 71:2723–2726.
   Google Scholar
• FUKUOKA M, NIITANI H, SUZUKI A, MOTOMIYA M, HASEGAWA K, NISHIWAKI Y, KURIAYMA T, ARIYOSHI Y, NEGORO S, MASUDA N, NAKAJIMA S, TAGUCHI T FOR THE CPT-11 LUNG CANCER STUDY GROUP: A Phase U study of CPT-11, a new derivative of camptothecin for pre- viously untreated non-small-cell lung cancer. J. Clin. Oncol. (1992) 10:16–20.
   PubMed Web of Science ®Google Scholar
• KARATO A, SASAKI Y, SHINICAI T, EGUCHI K, TAMURA T,OHE Y, OSHITA F, NISHIO M, KUNIKANE H, ARIOKA H, OHMATSU H, NAKASHIMA H, SHIRAISHI I, SAIJO N: Phase I study of CPT-nand etoposkle in patients with refrac-tory solid tumors. J. Clin. Oncol. (1993) 11:2030–2035.
   PubMed Web of Science ®Google Scholar
• MASUDA N, FUKUOKA M, KUDOH S, MATSUI K, KUSUNOKI Y, TAKADA M, NAKAGAWA K, HIRASHIMA T, TSUKADA H, YANA T, YOSHIKAWA A, ICUBO A, MAT-SUURA E, NITTA T, TAKIFUJI N, TERAKAWA K, NEGORO S: Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte col-ony-stimulating factor support for advanced lung can-cer. J. Clin. Oncol. (1994) 12:1833–1841.
   PubMed Web of Science ®Google Scholar
• MASUDA N, FUKUOKA M, KUDOH S, KUSUNOKI Y, MAT-SUI K, TAKIFUJI N, NAKAGAWA K, TAMANOI M, NITTA T, HIRASHIMA T, NEGORO S, TAKADA M: Phase I and pharmacologic study of kinotecan in combination with cisplatin for advanced lung cancer. Br. J. Cancer (1993) 68:777–782.
   PubMed Web of Science ®Google Scholar
• SHINKAI T, ARIOKA H, KUNIKANE H, EGUCHI K, SASAKIY, TAMURA T, OHE Y, OSHITA F, NISHIO M, KARATO A, OKAMOTO H, NAKASHIMA H, OHMATSU H, SHIRAISHI J, NOMURA N, SAIJO N: Phase I clinical trial of irinotecan (CPT-11), 7-ethy1-10-[4-(1-piperidlno)-1-piperidino]car-bonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res. (1994) 54:2636–2642.
   PubMed Web of Science ®Google Scholar
• HOCHSTER H, LIEBES L, SPEYER J, SORICH J, TAUBES B,ORATZ R, WERNZ J, CHACHOUA A, RAPHAEL B, VINCI RZ, BLUM RH: Phase I trial of low-dose continuous topote-can infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol. (1994) 12:553–559.
   PubMed Web of Science ®Google Scholar
• VERWEIJ J, LUND B, BEIJNEN J, PLANTING A, DE BOERDENNERT M, KOIER I, ROSING H, HANSEN H: Phase land pharmacokinetics study of topotecan, a new topoisom-erase I inhibitor. Ann Oncol. (1993) 4:673–678.
   PubMed Web of Science ®Google Scholar
• DEPIERRE A, LEMARIE E, DABOUIS G, GARNIER G, JA-COULET P, DALPHIN JC: A Phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am.J. Clin. Oncol. (CC7) (1991) 14:115–119.
   Google Scholar
• YOKOYAMA A, FURUSE K, NIITANI H: Multi-institutionalPhase 11 study of Navelbine (vinorelbine) in non-small cell lung cancer. Proc. ASCO (1992) 11:287.
   Google Scholar
• CRIVELLARI D, VERONESI A, SACCO C, MAGRI MD, BUONADONNA A, FOLADORE S, MONFARDINI S: Phase 11 study of vinorelbine (V) in 50 patients (ph) with non-small cell lung cancer (NSCLC). Proc. ASCO (1994) 13:355.
   Google Scholar
• SORENSEN JB: Current position of vinorelbine in cancerchemotherapy. Ann. Oncol. (1995) 6:105–107.
   PubMed Web of Science ®Google Scholar
• Asurn A, ZANNINI G, POGGI R, MORANDINI GC: Vi-norelbine monochemotherapy in non-small-cell lung cancer: experience in patients with low performance status. Monaldi Arch. Chest Div. (1994) 49:197–200.
   PubMedGoogle Scholar
• CLERIC' M, BRETTI S, CELANO A, PANVINI D, COMAN-DONE A, CASADIO C, LUPORINI G, BUMMA C: Non Small Cell Lung Cancer Treatment with Vinorelbine Mono-chemotherapy: A Phase 11 Study. Anticancer Res. (1995) 15:477–478.
   PubMed Web of Science ®Google Scholar
• PRONZATO P, LANDUCCI M, VAIRA F, VIGANI A, BERTELLIG: Failure of vinorelbine to produce responses in pre-treated non-small cell lung cancer patients. Anticancer Res. (1994) 14:1413–1415.
   PubMed Web of Science ®Google Scholar
• DEPIERRE A, CHASTANG C, QUOIX E, LEBEAU B, BLAN- CHON F, PAILLOT N, LEMARIE E, MILLERON B, MORO D, CLAVIER J, HERMAN D, TUCHAIS E, JACOULET P. BRE-CHOT JM, CORDIER JF, SOLAL-CELIGNY P, BADRI N, BESENRAL M: Vinorelbine versus vinorelbine plus cis-platin in advanced non-small cell lung cancer: a ran-domized trial. Ann. Oncol. (1994) 5:37–42.
   Google Scholar
• Randomised trial comparing vinorelbine against vinorelbine plus cisplatin in 208 patients.
   Google Scholar
• LE CHEVALIER T, BRISGAND D, DOUILLARD JY, PUJOL JL, ALBEROLA V, MONNIER A, RIVIERE A, LIANES P, CHOMY P, CIGOLARI S, GOD 11-RIED M, RUFFIE P, PANIZO A, GASPARD MH, RAVIOLI A, BESENVAL M, BESSON F, MARTINEZ A, BERTHAND P, TURSZ T: Randomized study of vinorelbine and cisplatin versus vindesine and cis-platin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J. Clin. Oncol. (1994) 12:360–367.
   PubMed Web of Science ®Google Scholar
• Randomised trial comparing vinorelbine against vinorelbine plus cisplatin, and against vindesine and cisplatin in 574 patients.
   Google Scholar
• GEBBIA V, CARUSO M, VALENZA R, TESTA A, CANNATA G, VERDERAME F, CIPOLLA C, CURTO G, OLIVERI D, CHLARENZE M, LATHERI MA, GESU GD, GEBBIA N: Vi-norelbine plus cisplatinum for the treatment of stage 1118 and IV non small cell lung carcinoma. Anticancer Res. (1994) 14:1247–1249.
   PubMed Web of Science ®Google Scholar
• Phase II trial of vinorelbine plus cisplatin with a 43% response rate.
   Google Scholar
• MASOTTI A, BORZELLINO G, ZANNINI G, LATERZA E, RICCI F, MORANDINI G: Efficacy and toxicity of vinorel-bine-carboplatin combination in the treatment of ad-vanced adenocarcinoma or large-cell carcinoma of the lung. Tutnori (1995) 81:112–116.
   Google Scholar
• Phase H trial of vinorelbine plus carboplatin showing a similar response rate to that achieved with vinorelbine plus cisplatin, and a well-tolerated toxicity profile.
   Google Scholar
• COMELLA P, CASARETTI R, DAPONTE A, BARTOLI GC, PARZIALE AP, PALMIERI G, COMELLA G: Combination of vinorelbine, cisplatin and etoposide in advanced non-small cell lung carcinoma: a pilot study. J. Chemother. (1994) 6:67–71.
   PubMed Web of Science ®Google Scholar
• BALDINI E, TIBALDI C, CHELLA A, ANGELETTI CA, ROMAN- INI A, ANDREI A, ALGERI R, SILVAN() G, CONTE PF: Combination chemotherapy with vinorelbine, ffosfa-mide, and cisplatin: a Phase II study in stage 11I13-IV non-small lung cancer. Semin. Oncol. (1994) 21(3 Suppl. 4):12–15.
   Google Scholar
• Phase II trial of vinorelbine, ifosfamide and cisplatin showing a 60% response rate.
   Google Scholar
• GRIDELLI C, DE PLACIDO S, PEPE R, INCORONATO P. AIROMA G, ROSSI A, PALAZZOLO G, BIANCO AR: Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. Eur. J. Cancer (1993) 29A:1729–1731.
   PubMed Web of Science ®Google Scholar
• GRIDELLI C, ROSSI A, PALAZZOLO G, PEPE R, AIROMA G,INCORONATO P, BIANCO AR: Mitomycin C, etoposide and vinorelbine (MEV ll) in the treatment of metastatic stage IV non small cell lung cancer. Cattedra di Oncologia Medica Tumori (1994) 80:128–130.
   Google Scholar
• CHANG AY, GARROW GC: Pilot study of Vinorelbine(Navelbine) and Paditaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin. Oncol. (1995) 22(2 Suppl. 5):66–71.
   Google Scholar
• VOICES EE, ROSENBERG RK, JAHANZEB M, CRAIG JB, GRALLA RJ, BELANI CP, JONES SE, HIGLEY JW, HOHNEKER JA: Multicenter Phase 11 Study of Weekly Oral Vinorel-bine for Stage IV Non-Small-Cell Lung Cancer. J. Clin. Oncol. (1995) 13:637–644.
   PubMed Web of Science ®Google Scholar
• MURPHY WK, FOSSELLA FV, WINN RJ, SHIN DM, HYNES HE, GROSS HM, DAVILLA E, LEIMERT J, DHINGRA H, RABER MN, KRAKOFF IH, HONG WK: Phase Il study of taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst. (1993) 85:384–388.
   PubMed Web of Science ®Google Scholar
• ICLASTERSKY J, SCULIER JP: Dose-finding study of pacli-taxel (Taxol) plus dsplatin in patients with non-small cell lung cancer. Semin. Oncol. (1994) 21:39–43.
   Web of Science ®Google Scholar
• GIACCONE G, HUIZING M, TEN BOKKEL HUININK W, KOOLEN M, POSTMUS P, VAN KRALINGEN K, VAN ZAND-WIJK N, VERMORKEN J, BEIJNEN J, DALESIO O, PINEDO H, VEENHOF C: Preliminary results of two dose-finding studies of parlitA xel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a Phase European Cancer Centre effort. Semin. Oncol. (1994) 21(5 Suppl. 8):34–38,
   Google Scholar
• ROWINSKY EK, GILBERT M, MCGUIRE WP, NOE DA, GRO-CHOW LB, FORASITERE AA, ETTINGER DS, LUBEJKO BG, CLARK B, SARTORIUS SE, CORNBLATH DR, HENDRICKS CM, DONEHOWER RC: Sequences of taxol and cisplatin: A Phase land pharmacologic study. J. Clin. Oncol. (1991) 9:1692–1703.
   PubMed Web of Science ®Google Scholar
• FOSSELLA FV, LEE JS, MURPHY WK, LIPPMAN SM, CA-LAYAG M, PANG A, CHASEN M, SHIN DM, GLISSON B, BENNER S, GLISSON B, CHASEN M, HONG WK, RABER M: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol. (1994) 12:1238–1244.
   PubMed Web of Science ®Google Scholar
• FRANCIS PA, RIGAS JR, KRIS MG, PISTERS KM, ORAZEM JP,\WOOLLEY KJ, HEELAN RT: Phase ll trial of docetaxel in patients with stage III and IV non-small-celllung cancer. Oncol. (1994) 12:1232–1237.
   Google Scholar
• CERNY T, KAPLAN S, PAVLIDIS N, SCHOFFSKI P, EPEL-BAUM R, VAN MEERBEEK J, WANDERS J, FRAKLIN FIR, KAYE S: Docetaxel (Taxotere) is active in non-small-cell lung cancer: a Phase 11 trial of the EORTC Early Clinical Trials Group (ECTG). Br. J. Cancer (1994) 70:384–387.
   PubMed Web of Science ®Google Scholar
• MILLER VA, RIGAS JR, FRANCIS PA, GRANT SC, PISTERS KM, VENKATRAMAN ES, WOILFY K, HEELAN RT, KRIS MG. Phase 11 trial of a 75 mg/m2 dose of docetaxel with prednisotte premedication for patients with advanced non-small cell lung cancer. Cancer (1995) 75:968–972.
   Google Scholar
• FOSSELLA FV, LEE JS, SHIN DM, CALAYAG M, HLTBER M, PEREZ-SOLAR R, MURPHY WK, LIPPMAN S, BENNER S,GLISSON B, CHASEN M, HONG WK, RABER M: Phase 11 study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J. Gun. Oncol. (1995) 13:645–651.
   Web of Science ®Google Scholar
• A response rate of 21% was observed with docetaxel as second-line chemotherapy in patients refractory to prior platinum containing regimens.
   Google Scholar
• MUNSHI NC, SETTZ DE, FOSSELLA F, LIPPMAN SM, EIN-HORN LH: Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer. Invest. New Drugs (1993) 11:87–90.
   Google Scholar
• MAROUN J, RUCKDESCHEL J, NATALE R, MORGAN R, DALLAIRE B, SISK R, GYVES J: Multicenter Phase II study of breguinar sodium in patients with advanced lung cancer. Cancer Cbemother. Pbarmacol. (1993) 32:64–66.
   PubMed Web of Science ®Google Scholar
• WARR D, MCKINNEY S, TANNOCK I: Influence of meas-urement error on assessment of response to anticancer chemotherapy: Proposal for new criteria of tumor response. J. Cltn. Oncol. (1984) 2:1040–1046.
   PubMed Web of Science ®Google Scholar
• NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual pa-tients from 52 randomised clinical trials. Br. Med. J. (1995) 311:899–909.
   PubMed Web of Science ®Google Scholar